Allarity Therapeutics secures first CLIA lab services contract

TARPON SPRINGS, Fla. - Allarity Therapeutics, Inc., a clinical-stage pharmaceutical company developing a drug candidate called stenoparib, has secured its first revenue-generating contract under its new CLIA-certified laboratory services strategy. The agreement involves a European biotechnology company that will utilize Allarity's expertise to support the implementation of a precision oncology predictive device for use in the United States.

Allarity obtained the necessary CLIA certification from the U.S. regulatory authority in July 2026, enabling its Hørsholm laboratory to perform internal biomarker testing for stenoparib and its DRP companion diagnostic strategy. The successful completion of this program could lead to ongoing commercial testing and CLIA-related service revenues.

This marks a significant step forward for Allarity's newly established CLIA laboratory services strategy, which complements its existing revenue streams from standard gene expression and DRP services.